Compare CSX Corporation (CSX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? CSX Corporation trades at $49.91 (market cap $92.55B), while State Street SPDR S&P Biotech ETF trades at $159.57. The key difference: CSX Corporation pays a 1.12% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| CSX | XBI | |
|---|---|---|
Market Cap | $92.55B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $53.21 | $164.28 |
52-Week Low | $32.05 | $86.92 |
Enterprise Value | $110.52B | — |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.12, down 0.3% on the day, with a neutral technical signal. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and margin expansion. The stock's valuation ratios, including a P/E of 29.05 and P/S of 6.41, reflect a premium pricing relative to historical levels. Analyst consensus is bullish with a $52.57 price target, supported by 58.69% buy ratings.
The outlook for CSX is positive, with projected 2026 revenue growth and improved cash flow. Key opportunities include strong intermodal demand and operational efficiency gains. Risks involve competitive pressures, fuel cost volatility, and potential economic slowdowns affecting freight volumes. The stock's current level offers a moderate upside to the consensus target, balanced by elevated valuation multiples.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
